Drugs / OX118
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07020156 | Apr → Oct 2025 overdue | immune system disorder | Oxion Biologics AB | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OX118 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07020156 ↗ |
| Modality | Monoclonal antibody | “human monoclonal antibody” NCT07020156 ↗ |
| Route | Intravenous | “Route of administration: intravenous infusion” NCT07020156 ↗ |